<?xml version="1.0" encoding="UTF-8"?>
<p>Generally, from the management point to the site of antiviral activities, pharmaceuticals may encounter a diversity of biological barriers [
 <xref rid="B130-nanomaterials-10-01072" ref-type="bibr">130</xref>,
 <xref rid="B131-nanomaterials-10-01072" ref-type="bibr">131</xref>,
 <xref rid="B132-nanomaterials-10-01072" ref-type="bibr">132</xref>]. One main instance is the setting up of latent reservoirs in cellular and structurally immune-privileged sites, for example, the blood-brain or blood-testis barrier. Therapeutic size is a pivotal consideration in successful drug development for transmissible diseases, where entrance to unreachable compartments, namely viruses crossing the blood-brain barrier, is obligatory for preventing the creation of dormant infections with persistent replication at low levels [
 <xref rid="B133-nanomaterials-10-01072" ref-type="bibr">133</xref>]. Nanoparticulate drug transporters are generally proficient at crossing such membranes and are thus a favorable means to be studied for avoiding this impediment. The utilization of NPs or nanocarriers to ease entrance into diverse subcellular sections is consequently an outstanding choice because of their small size, architecture, or specific properties; they have been therefore developed for viral detection or treatment and are adequately capable of surmounting natural obstructions to attain specific and targeted delivery [
 <xref rid="B9-nanomaterials-10-01072" ref-type="bibr">9</xref>].
</p>
